研发服务

Search documents
50家新型研发机构会聚山东产研院,共探高质量发展路径
Qi Lu Wan Bao· 2025-08-22 10:44
为深入探讨新型研发机构发展路径,更好赋能现代化产业体系建设,8月21日,山东产研院在济南组织召开"新型研发机构高质量发展研 讨会"。会议邀请省内外近50家新型研发机构的100余名代表,围绕新型研发机构高质量发展与创新机制等议题进行深入研讨。 齐鲁晚报·齐鲁壹点记者 王皇 通讯员 孙凤巧 研讨会还特别邀请来自国内外知名新型研发机构的一线管理者分享实战经验,长三角国家技术创新中心办公室主任张冬梅、德国史太白 技术管理中国总部总裁马娟、沈阳产业技术研究院副院长程凯文、山东省工业技术研究院副院长孟凯分别带来新型研发机构的国际化运 作与机制借鉴、地方新研发机构的落地实践、省内机构在机制创新中的探索与挑战等经验分享。 新型研发机构作为国家战略科技力量的重要部署和体制机制改革的"试验田",其高质量发展离不开区域间、机构间的开放合作,实现优 势互补、协同发展。与会代表还就新型研发机构的体制机制改革、活力人才生态构建、可持续发展路径和深化开放合作等议题进行了深 入交流。 山东产研院相关负责人表示,与会专家学者的真知灼见,为破解新型研发机构发展难题、明晰未来方向提供了宝贵的理论指导和实践参 考,下一步,山东产研院将持续发挥平台优 ...
架设科创与产业融合的向“新”桥梁——专访长三角国家技术创新中心主任刘庆
Xin Hua She· 2025-07-28 05:27
Core Viewpoint - The integration of technological innovation and industrial innovation is essential for developing new productive forces, with a focus on bridging the technology chain and the industrial chain [1] Group 1: Innovation Strategy - The Long Triangle National Technology Innovation Center aims to connect global innovation resources with the Yangtze River Delta, enhancing regional innovation resource allocation [2] - The center operates under the principle of "R&D as industry, technology as commodity," promoting a "team holding" model where research teams hold equity in operating companies [2][3] - The center has established nine overseas innovation incubation platforms and strategic partnerships with over 200 universities and research institutions [2] Group 2: Achievements in Research and Development - The center has made significant advancements, including breakthroughs in critical technologies like single crystal blades for aircraft engines and the development of semiconductor unicorns valued at billions [3] - Approximately 7,000 graduate students are actively engaged in the industry, contributing to high-quality economic development [3] Group 3: Addressing Industry Needs - There are existing barriers in the integration of innovation and industry, such as the disconnect between research outcomes and enterprise needs [4] - The center collaborates with over 500 companies to establish joint innovation centers, identifying over 3,000 technical needs that companies are willing to fund [4] - The center has facilitated over 1,200 cooperation intentions with a total contract value exceeding 3.5 billion [4] Group 4: Collaborative Research Models - The center employs a "crowdsourced research" model to address common technical needs across industries, encouraging upstream and downstream enterprises to pool resources for targeted research [5] Group 5: Talent Development - The integration of education and technology talent is crucial, with a focus on breaking down barriers between universities, enterprises, and research institutions [7] - A significant percentage of engineering faculty lack industry experience, which can lead to a disconnect between academic research and industry needs [7] - The establishment of the Jicui Education Foundation aims to promote paid internships for university students, enhancing their practical experience and understanding of the industry [7]
武汉海特生物制药股份有限公司
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-04-20 23:57
Group 1 - The biopharmaceutical industry is a rapidly growing strategic emerging industry globally, with significant government support and innovation driving its development [5][7] - The global biopharmaceutical market grew from $261.1 billion in 2018 to $363.8 billion in 2022, with a compound annual growth rate (CAGR) of 8.6%, and is expected to reach $783.2 billion by 2030, with a CAGR of approximately 10.1% from 2022 to 2030 [5] - In China, the biopharmaceutical market is projected to grow from $45.2 billion in 2019 to $66.5 billion in 2023, with a CAGR of 10.13%, and is expected to reach $162.8 billion by 2030, with a CAGR of approximately 13.64% from 2023 to 2030 [7] Group 2 - The company specializes in the production and sales of biopharmaceuticals, including the first commercialized nerve growth factor product, Jinlujie, which has been widely used in clinical applications for nerve injury repair [15][16] - The company’s subsidiary, Tianjin Hankan, is a well-known CRO-CDMO integrated service provider, offering a comprehensive range of drug development services from research to clinical trials and production [11][22] - The company has developed over 200 products for more than 600 enterprises, with significant achievements in the development of generic drugs and innovative drugs [12][11] Group 3 - The company has received various accolades, including being recognized as a "National Specialized and New 'Little Giant' Enterprise" and ranking among the top 50 innovative enterprises in the pharmaceutical industry [13] - The company’s product pipeline includes innovative drugs such as injection of Epinavamine, a targeted anti-tumor drug, and other pharmaceutical products that address various medical needs [17][18][20] - The company has made significant advancements in drug registration, with several products receiving approval from the National Medical Products Administration [37]